Workflow
云南白药(000538) - 2025年4月11日调研活动附件之投资者调研会议记录(一)
YUNNAN BAIYAOYUNNAN BAIYAO(SZ:000538)2025-04-15 08:58

Financial Performance - In 2024, the company achieved a revenue of CNY 40.033 billion, a year-on-year increase of 2.36% [2] - The net profit attributable to shareholders reached CNY 4.749 billion, up 16.02% from CNY 4.094 billion in the previous year [2] - The net profit excluding non-recurring items was CNY 4.523 billion, a 20.18% increase from CNY 3.764 billion [2] - Operating cash flow net amount was CNY 4.297 billion, growing by 22.68% [3] - The weighted average return on equity was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share were CNY 2.66, reflecting a growth of 16.16% [3] Business Structure and Efficiency - Industrial revenue accounted for 36.14% of total revenue, with an industrial revenue growth rate of 5.30% [3] - The industrial gross profit margin was 65.93%, up 1.69 percentage points from the previous year [3] - Sales expenses decreased by 2.26% and management expenses decreased by 1.98% compared to the previous year [4] Asset Management - As of the end of the reporting period, total assets were CNY 52.914 billion, with net assets attributable to shareholders at CNY 38.832 billion [4] - The debt-to-asset ratio stood at 26.55% [4] - Cash and cash equivalents amounted to CNY 10.888 billion [4] R&D Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024 and completed its I/IIa phase clinical summary report in November [5] - The INR102 injection clinical trial application was approved for prostate cancer treatment [5] Health Products Division - The health products division generated revenue of CNY 6.526 billion, a year-on-year increase of 1.6% [6] - Profit from the health products division was CNY 2.191 billion, up 8.36% [6] - Yunnan Baiyao toothpaste maintained the top market share in the domestic oral care market [7] - The Yangyuanqing hair care products achieved sales of CNY 422 million, a growth of 30.3% [7] Dividend Distribution - The company proposed a cash dividend of CNY 11.85 per 10 shares, totaling CNY 2.164 billion for the 2024 special dividend [8] - The total cash dividend for 2024 is CNY 23.98 per 10 shares, amounting to CNY 4.279 billion, which represents 90.09% of the net profit attributable to shareholders [8]